-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the development of the domestic innovative drug industry is in full swing, and a large number of new drugs have been approved one after another
.
But it should be noted that the research and development of innovative drugs is by no means easy, and risks and benefits coexist
.
Since the beginning of this year, many pharmaceutical companies have been defeated in the process of developing innovative drugs
.
Recently, Shanghai Fosun Pharmaceutical (Group) Co.
, Ltd.
issued an announcement stating that its holding subsidiary Wanbang Biochemical Pharmaceutical Group Co.
, Ltd.
has decided to terminate the clinical trials and subsequent development of the new class 1 drug, Vanggliflozin Tablets, which was previously in China.
The territory (excluding Hong Kong, Macau and Taiwan) is in phase I clinical trials
.
Public information shows that vanagliflozin is a new structure of SGLT-2 inhibitor, independently developed by Sirona Biochem Corp
.
.
Since the new drug is still in the phase I clinical trial stage, and a number of SGLT-2 inhibitors have been launched at home and abroad, the market competition has been relatively fierce.
Based on the comprehensive evaluation of the new drug's follow-up development investment and market value and other factors, it is reasonable With the allocation of R&D resources and focusing on advantageous projects in the R&D pipeline, Wanbang Pharmaceutical decided to terminate clinical trials and subsequent development of the drug
.
In addition to Fosun Pharma, on August 18, the drug clinical trial registration and information disclosure platform showed that Hengrui's SHR-1314 injection in the treatment of adult moderate to severe plaque psoriasis phase II clinical trial status has also changed to Active termination
.
On August 16, Zejing Pharmaceutical also issued an announcement, deciding to terminate the further development of Donafenib monotherapy for this indication
.
From the fact that many pharmaceutical companies have successively terminated the research and development of innovative drugs, it is obvious that the research and development of new drugs is a technological innovation with high risk and low success rate.
Every step in this process may lead to failure
.
It is understood that since this year, no less than 20 pharmaceutical companies have announced the termination or suspension of research and development in the field of drugs
.
Among them, in addition to domestic pharmaceutical companies, there are also large foreign pharmaceutical companies
.
As a few days ago, the research and development of Merck’s HIV project has also suffered a major blow.
After discovering that the white blood cell count of the subject has decreased, the company announced that it will suspend the development of the MK-8507 project that the company claims is "very important".
.
It is understood that Merck has been committed to developing a weekly treatment plan for HIV patients to use MK-8507 in combination with islatravir.
However, in a phase II trial, patients receiving the highest dose of MK-8507 were found to have lymphocytes and The CD4+ T cell count decreases, and this may increase the possibility of infection in these patients
.
Currently, Merck has stopped the drug in the trial and will continue to monitor 161 study participants
.
However, it also stated that it "still has full confidence in the overall development of islatravir" and will continue to develop the drug for its internal projects and cooperation with Gilead
.
In fact, it is a long and complicated process from the laboratory to the launch of a new drug, and every step in this process may lead to failure
.
Therefore, there are many reasons why pharmaceutical companies terminate new drug R&D projects, either by allocating R&D resources, eliminating non-essential product lines, or adjusting R&D structure and R&D direction, or considering market profit and risk
.
The industry believes that, focusing on the medium and long-term development, under the background that innovative research and development is still the general trend of the industry, the termination of research and development due to various reasons in the future is expected to become the norm in the industry
.
.
But it should be noted that the research and development of innovative drugs is by no means easy, and risks and benefits coexist
.
Since the beginning of this year, many pharmaceutical companies have been defeated in the process of developing innovative drugs
.
Recently, Shanghai Fosun Pharmaceutical (Group) Co.
, Ltd.
issued an announcement stating that its holding subsidiary Wanbang Biochemical Pharmaceutical Group Co.
, Ltd.
has decided to terminate the clinical trials and subsequent development of the new class 1 drug, Vanggliflozin Tablets, which was previously in China.
The territory (excluding Hong Kong, Macau and Taiwan) is in phase I clinical trials
.
Public information shows that vanagliflozin is a new structure of SGLT-2 inhibitor, independently developed by Sirona Biochem Corp
.
.
Since the new drug is still in the phase I clinical trial stage, and a number of SGLT-2 inhibitors have been launched at home and abroad, the market competition has been relatively fierce.
Based on the comprehensive evaluation of the new drug's follow-up development investment and market value and other factors, it is reasonable With the allocation of R&D resources and focusing on advantageous projects in the R&D pipeline, Wanbang Pharmaceutical decided to terminate clinical trials and subsequent development of the drug
.
In addition to Fosun Pharma, on August 18, the drug clinical trial registration and information disclosure platform showed that Hengrui's SHR-1314 injection in the treatment of adult moderate to severe plaque psoriasis phase II clinical trial status has also changed to Active termination
.
On August 16, Zejing Pharmaceutical also issued an announcement, deciding to terminate the further development of Donafenib monotherapy for this indication
.
From the fact that many pharmaceutical companies have successively terminated the research and development of innovative drugs, it is obvious that the research and development of new drugs is a technological innovation with high risk and low success rate.
Every step in this process may lead to failure
.
It is understood that since this year, no less than 20 pharmaceutical companies have announced the termination or suspension of research and development in the field of drugs
.
Among them, in addition to domestic pharmaceutical companies, there are also large foreign pharmaceutical companies
.
As a few days ago, the research and development of Merck’s HIV project has also suffered a major blow.
After discovering that the white blood cell count of the subject has decreased, the company announced that it will suspend the development of the MK-8507 project that the company claims is "very important".
.
It is understood that Merck has been committed to developing a weekly treatment plan for HIV patients to use MK-8507 in combination with islatravir.
However, in a phase II trial, patients receiving the highest dose of MK-8507 were found to have lymphocytes and The CD4+ T cell count decreases, and this may increase the possibility of infection in these patients
.
Currently, Merck has stopped the drug in the trial and will continue to monitor 161 study participants
.
However, it also stated that it "still has full confidence in the overall development of islatravir" and will continue to develop the drug for its internal projects and cooperation with Gilead
.
In fact, it is a long and complicated process from the laboratory to the launch of a new drug, and every step in this process may lead to failure
.
Therefore, there are many reasons why pharmaceutical companies terminate new drug R&D projects, either by allocating R&D resources, eliminating non-essential product lines, or adjusting R&D structure and R&D direction, or considering market profit and risk
.
The industry believes that, focusing on the medium and long-term development, under the background that innovative research and development is still the general trend of the industry, the termination of research and development due to various reasons in the future is expected to become the norm in the industry
.
